SAVA
Cassava Sciences, Inc.2.9300
+0.1300+4.64%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
141.54MP/E (TTM)
-Basic EPS (TTM)
-2.22Dividend Yield
0%Recent Filings
8-K
Q4 2025 results, TSC update
Filana Therapeutics reported $91.0M net loss for 2025, up from $24.3M in 2024 after no warrant gain repeat, with cash at $95.5M versus $128.6M prior year. R&D expenses plunged 62% to $26.6M as Alzheimer's program ended, shifting to cheaper TSC-related epilepsy efforts amid FDA clinical hold response. Cash to hit $47-50M by June 2026. Litigation weighs heavy.
10-K
FY2025 results
Filana Therapeutics posted a $91M net loss for FY2025 ended December 31, 2025, with R&D expenses plunging 62% to $26.6M as the Alzheimer's program wound down by Q2, while G&A held near $69M amid $35M litigation reserves. Q4 saw R&D at minimal levels versus prior quarters' Phase 3 wind-down, reflecting TSC-related epilepsy pivot; cash burned $32M operationally, ending at $95.5M after warrant proceeds exhausted. FDA's December 15 full clinical hold stalled simufilam proof-of-concept trials, delaying beyond H1 2026. No capex spikes or buybacks; leasing yielded modest Q4 losses. No annual guidance disclosed. Clinical holds threaten quarterly momentum.
8-K
Name change to Filana effective
Filana Therapeutics, formerly Cassava Sciences, completed its name change effective March 10, 2026, via Delaware certificate amendment and updated bylaws that also modernize stockholder meeting rules. Shares switch to FLNA ticker on Nasdaq March 11. Rebrand spotlights filamin A modulation for TSC-related epilepsy. New website: filanatx.com.
8-K
DOJ closes Cassava inquiry
Cassava Sciences announced on February 19, 2026, that the DOJ Fraud Section closed its inquiry into research misconduct allegations tied to the dismissed United States v. Wang indictment. This follows a September 2024 SEC settlement on disclosure charges, with full cooperation from the company. Investigations now ended. Cassava refocuses on TSC-related epilepsy treatments amid inherent drug development risks.
8-K
Settles securities class action
Cassava Sciences settled its consolidated securities class action lawsuit covering purchases from September 14, 2020, to October 12, 2023, agreeing to pay $31.25 million for full releases of all claims against the company and officers. The binding term sheet, reached via mediation on December 19, 2025, awaits court approval; funds go into escrow in January 2026. No admission of wrongdoing. Company reserved the amount in Q2 2025.
IPO
Employees
Sector
Industry
ALZN
Alzamend Neuro, Inc.
2.16+0.05
ANVS
Annovis Bio, Inc.
3.93+0.15
ATHE
Alterity Therapeutics Limited
3.07+0.06
AVXL
Anavex Life Sciences Corp.
4.02-0.12
BIVI
BioVie Inc.
1.43+0.00
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
IGC
IGC Pharma, Inc.
0.34+0.00
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
NERV
Minerva Neurosciences, Inc
4.17+0.13
SVRA
Savara, Inc.
6.43-0.18